News Sentiment

PRCT sentiment intelligence

Procept Biorobotics Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 20.89 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.7% over one week, -18.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Procept Biorobotics Corp stock hits 52-week low at 19.2 USD

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.7% Price digesting
Trend fit Trend inactive -18.7% over four weeks
Fair value -57.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 10
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
Stock Titan 5
TradingView 5
Sahm 4
MT Newswires 3
Investing.com 3
Insider Monkey 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 25
Analyst action 9
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
Investing.com Nigeria Direct company coverage

Procept Biorobotics Corp stock hits 52-week low at 19.2 USD

Procept Biorobotics Corp (PRCT) stock has fallen to a new 52-week low of $19.21, marking a significant 63.52% decline over the past year. Despite this downturn and a market capitalization of $1.21 billion, InvestingPro indicates the stock may be undervalued with a Fair Value esti

Tone
Negative 28/100
Event
Market update
Published
14 Jul 2026 22:40
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Procept Biorobotics Corp stock hits 52-week low at 19.2 USD By Investing.com

Procept Biorobotics Corp (PRCT) stock has reached a 52-week low of $19.21, marking a significant 63.52% decline over the past year. Despite the downturn, InvestingPro analysis suggests the stock might be undervalued with a Fair Value estimate of $28.01. Recent news indicates the

Tone
Negative 40/100
Event
Market update
Published
14 Jul 2026 22:14
Source
Investing.com South Africa
scanx.trade Direct company coverage

PROCEPT BioRobotics to report Q2 2026 results on August 4

PROCEPT BioRobotics Corporation will release its financial results for the second quarter of 2026 after the market closes on August 4, 2026. Following the release, the company will host a conference call at 4:30 p.m. Eastern Time to discuss their performance. A live webcast and a

Tone
Negative 40/100
Event
Earnings
Published
14 Jul 2026 22:14
Source
scanx.trade
The Manila Times Direct company coverage

PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will report its Q2 2026 financial results after market close on Tuesday, August 4, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results. Interested parties can access

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 20:14
Source
The Manila Times
Stock Titan Direct company coverage

Hear PROCEPT BioRobotics’ Q2 update Aug. 4 at 4:30 p.m.

PROCEPT BioRobotics (Nasdaq: PRCT) announced it will report its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, which will be accessible via webcast and archived for at least 90

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 19:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Truist Financial Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)

Truist Financial analyst Richard Newitter maintained a Hold rating on PROCEPT BioRobotics (PRCT) and set a price target of $25.00. The company reported a quarterly revenue of $83.13 million and a GAAP net loss of $31.64 million, with analyst consensus remaining a "Moderate Buy."

Tone
Negative 38/100
Event
Analyst action
Published
08 Jul 2026 20:10
Source
The Globe and Mail
Finviz Direct company coverage

PRCT - Procept BioRobotics Corp Dividends

This article provides a detailed financial overview of Procept BioRobotics Corp (PRCT), including its latest stock performance, key financial metrics, and insider transaction data. It highlights the company's current stock price, recent percentage change, market capitalization, a

Tone
Negative 32/100
Event
Market update
Published
03 Jul 2026 18:09
Source
Finviz
Bitget Direct company coverage

Truist Securities downgraded the stock rating of PROCEPT BioRobotics Corp from "Buy" to "Hold"

Truist Securities has downgraded PROCEPT BioRobotics Corp's stock rating from "Buy" to "Hold" and significantly reduced its target share price from $30 to $25. This decision reflects a re-evaluation by the institution regarding the company's investment prospects. The article also

Tone
Negative 18/100
Event
Analyst action
Published
03 Jul 2026 05:40
Source
Bitget
Stock Titan Direct company coverage

If You Invested $1,000 in Procept Biorobotics Corp (PRCT)

This article analyzes the historical performance of Procept Biorobotics Corp (PRCT) stock, detailing how a $1,000 investment would have fared over different periods. It also provides an overview of the company's focus on surgical robotics for urology, specifically its AQUABEAM an

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:09
Source
Stock Titan
Investing.com Direct company coverage

Truist cuts Procept BioRobotics stock rating on reimbursement concerns

Truist Securities downgraded Procept BioRobotics Corp (NASDAQ:PRCT) to Hold from Buy and lowered its price target due to concerns over reimbursement for its Aquablation procedures. This downgrade follows a proposal from the Centers for Medicare and Medicaid Services to increase r

Tone
Negative 27/100
Event
Analyst action
Published
02 Jul 2026 21:39
Source
Investing.com
TradingView Direct company coverage

Enterprise value to EBIT forward of PROCEPT BioRobotics Corp. – BX:PRCT

This page displays the enterprise value to EBIT forward for PROCEPT BioRobotics Corp. (BX:PRCT). It is part of the financial data available for the company on the platform. The information is provided by various financial data services.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 08:09
Source
TradingView
Sahm Direct company coverage

PROCEPT BioRobotics (PRCT) Is Up 7.2% After WATER IV Milestones Spotlight Aquablation’s Oncology Potential – Has The Bull Case Changed?

PROCEPT BioRobotics (PRCT) saw its stock rise by 7.2% following milestones in its WATER IV prostate cancer trials, suggesting Aquablation therapy could expand into urologic oncology. This development could broaden the company's market beyond benign prostatic hyperplasia, reinforc

Tone
Positive 73/100
Event
Market update
Published
01 Jul 2026 05:41
Source
Sahm
Insider Monkey Direct company coverage

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

Evercore ISI has initiated coverage on PROCEPT BioRobotics (PRCT) with an "Outperform" rating and a $30 price target, highlighting the potential of Aquablation therapy. The company recently achieved two significant milestones in its WATER IV prostate cancer clinical program, incl

Tone
Positive 75/100
Event
Analyst action
Published
30 Jun 2026 02:10
Source
Insider Monkey
TradingView Direct company coverage

Price to earnings forward of PROCEPT BioRobotics Corp. – BX:PRCT

This article provides financial data for PROCEPT BioRobotics Corp. (BX:PRCT), specifically focusing on its price-to-earnings forward metric. The content highlights the period, value, and change percentage of this financial indicator, noting that the data is provided by ICE Data S

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of PROCEPT BioRobotics Corp. – BX:PRCT

This article provides the "Price to sales forward" financial metric for PROCEPT BioRobotics Corp. (BX:PRCT) on the TradingView platform. It shows the company's ticker, exchange, and confirms that the market is currently closed with no trades. The data presented is stated as being

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

PRCT Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for PROCEPT BioRobotics Corp. (PRCT) stock, based on analyst opinions. It highlights the current stock price, market capitalization, volatility, and details on past earnings, revenue, and upcoming earnings reports. Additionally, i

Tone
Positive 66/100
Event
Earnings
Published
28 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of PROCEPT BioRobotics Corp. – BX:PRCT

This page displays the "Price to book forward" financial metric for PROCEPT BioRobotics Corp. (PRCT) on the BX Swiss exchange. It indicates that the financial data is 'Made by humans' and sources its market and reference data from ICE Data Services and FactSet, respectively. The

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 01:10
Source
TradingView
Investing.com Direct company coverage

Evercore ISI initiates Procept BioRobotics stock with outperform rating

Evercore ISI initiated coverage on Procept BioRobotics (NASDAQ:PRCT) with an outperform rating and a $30 price target, highlighting the company's strong long-term fundamentals despite short-term challenges. The firm believes Procept's Aquablation technology has superior clinical

Tone
Positive 74/100
Event
Analyst action
Published
25 Jun 2026 02:10
Source
Investing.com
Investing.com Canada Direct company coverage

Evercore ISI initiates Procept BioRobotics stock with outperform rating By Investing.com

Evercore ISI has initiated coverage on Procept BioRobotics (NASDAQ:PRCT) with an outperform rating and a $30.00 price target, citing the company's strong long-term fundamentals despite short-term challenges. The firm believes Procept's Aquablation technology has superior clinical

Tone
Positive 70/100
Event
Analyst action
Published
24 Jun 2026 10:40
Source
Investing.com Canada
Insider Monkey Direct company coverage

5 Best Robotics and Automation Stocks to Invest In

This article lists the top 5 robotics and automation stocks to consider for investment, highlighting PROCEPT BioRobotics Corp. as one of them. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is praised for its advancements in prostate cancer treatment with its Aquablation therapy, partic

Tone
Positive 63/100
Event
Market update
Published
24 Jun 2026 03:30
Source
Insider Monkey
Stocktwits Direct company coverage

PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20

Bank of America has downgraded PROCEPT BioRobotics (PRCT) to 'Underperform' from 'Neutral' and cut its price target to $20 from $38, following the company's Q4 results which missed street estimates. Concerns were raised about earnings visibility, profitability, and execution, as

Tone
Negative 20/100
Event
Earnings
Published
23 Jun 2026 04:10
Source
Stocktwits
Sahm Direct company coverage

PROCEPT BioRobotics (PRCT) Is Down 6.5% After Institutional Ownership Surges Past Shares Outstanding Has The Bull Case Changed?

PROCEPT BioRobotics (PRCT) has experienced a 6.5% stock drop despite strong year-over-year revenue and net profit growth, coupled with a surge in institutional ownership exceeding total shares outstanding. The company's investment narrative centers on Aquablation becoming a stand

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 13:40
Source
Sahm
Sahm Direct company coverage

PROCEPT BioRobotics (PRCT) Stock Could Be 14% Undervalued After Growth Outlook Holds

Despite a recent stock decline, PROCEPT BioRobotics (PRCT) is considered 14% undervalued with a fair value of $25.26 per share, even though it currently trades at $21.72. Analyst commentary highlights rapid revenue growth, expanding gross margins, and lower management guidance. A

Tone
Positive 70/100
Event
Guidance
Published
20 Jun 2026 12:40
Source
Sahm